Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan in advanced extrapulmonary neuroendocrine neoplasms
NCT07077564Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in neuroendocrine neoplasms (NENs), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT07077564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077564.